ストックスクリーナーアプリを入手
12.10
0.82%
-0.10
アフターアワーズ：
11.91
-0.19
-1.57%
Relay Therapeutics Inc (RLAY) 最新ニュース
Relay Therapeutics, Inc. Stock 12‑Month Price Target Raised to $21.25, Implies 74% Upside - TradingView
Relay Therapeutics Q1 2026 earnings preview - MSN
Relay Therapeutics (RLAY) price target increased by 14.03% to 21.42 - MSN
Relay Therapeutics (RLAY) surges 16.4%: Is this an indication of further gains? - MSN
Relay Therapeutics, Inc.Common Stock (NQ: RLAY - FinancialContent
Point72 Reports Zero Ownership in Relay Therapeutics (RLAY) - Stock Titan
Insider Sell Alert: Thomas Catinazzo Sells Shares of Relay Thera - GuruFocus
Relay Therapeutics CFO Catinazzo sells $227,840 in stock - Investing.com
Relay Therapeutics CFO Catinazzo sells $227,840 in stock By Investing.com - Investing.com UK
Relay Therapeutics (RLAY) CFO sells 17,717 shares in planned trade - Stock Titan
Thomas J. Catinazzo (RLAY) reports multiple 10b5-1 sales totaling tens of thousands of shares - Stock Titan
RLAY Stock Chart | RELAY THERAPEUTICS INC (NASDAQ:RLAY) - ChartMill
H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) - Yahoo Finance
How Relay’s Phase 3 Zovegalisib Breast Cancer Push Could Reshape Relay Therapeutics’ (RLAY) Investment Story - simplywall.st
Insider Monkey News - Insider Monkey
RLAY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Relay Therapeutics (NASDAQ:RLAY) Downgraded by Wall Street Zen to Sell - MarketBeat
Relay Therapeutics (RLAY) Eps Diluted (TTM) - Zacks Investment Research
Relay Therapeutics, Inc. (NASDAQ:RLAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Moomoo
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance
Relay Therapeutics, Inc. (RLAY) reports Q1 loss, lags revenue estimates - MSN
Relay Therapeutics Q1 Loss Narrows, Revenue Fall - Moomoo
Relay Therapeutics (RLAY) Q1 Loss Of US$73.3 Million Tests Growth At A Loss Narrative - Sahm
Oppenheimer Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $18 - Moomoo
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $18 to $21 - Moomoo
Relay Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates - Investing News Network
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Goldman Sachs Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Relay Therapeutics (NASDAQ:RLAY) Beats Q1 Estimates but Slips on Wider Loss and Lack of Guidance - ChartMill
Earnings Flash (RLAY) Relay Therapeutics, Inc. Reports Q1 Revenue $3.0M, vs. FactSet Est of $5.6M - marketscreener.com
Relay breast cancer drug gets FDA breakthrough, Phase 3 next - Stock Titan
Earnings Flash (RLAY) Relay Therapeutics, Inc. Reports Q1 Revenue $3.0M, Vs. FactSet Est of $5.6M - Moomoo
[10-Q] Relay Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Relay Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
FDA BTD, trial advances and 2029 cash runway for Relay Therapeutics (Nasdaq: RLAY) - Stock Titan
MSN Money - MSN
Relay Therapeutics : RLAY - 24/7 Wall St.
Relay Therapeutics Advances Zovegalisib To Phase 3 As Valuation Gap Persists - Yahoo Finance
Relay Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
$207B Market Shift: The Race for Fast Track Approval in Oncology - Quantisnow
2.53%
大文字化:
|
ボリューム (24 時間):